Life Sciences Archive » September, 2020

Life Sciences - September, 2020

373 articles

• DOJ Charges 345 In Health Fraud Schemes Topping $6B
• DEA Exploiting Doctrine To Keep Pot Illegal, 9th Circ. Hears
• House Dems Lay Into Pharma CEOs, Urge Price Negotiations
• Teva Inks Patent Deal With Collegium Over Painkiller
• UK Court Rules Meril Infringes Heart Valve IP, But Some Claims Are Invalid
• Purdue Pharma Gets OK For Payments, Opioid Suit Shield
• Gov't Contracts Of The Month: Virus, Nukes And Int'l Travel
• 3rd Circ. Wipes Out FTC's $448M AbbVie Win
• Law360's The Term: The Impact Of Amy Coney Barrett
• Alice Dooms DNA Analysis Patents In Biotech Co.'s Suit
• Atlanta Homeowners Say Sterigenics Plant Cut Property Value
• Cannabis Co. Fights Shareholders' Bid To DQ Attys From Suit
• College Coronavirus Q&A: Cal State's General Counsel
• Pot Co. Says TCPA Plaintiff Signed Up For Texts Before Suing
• Boehringer Ingelheim Wins Pradaxa Wrongful Death Suit
• Walgreens Asks 9th Circ. To Decertify Theranos Class
• Immunomedics Hit With Investor Suit To Halt $21B Gilead Deal
• How Amy Coney Barrett Could Upend Abortion Rights
• Key Contractual Protections For Cos. In The PPE Space
• What We Know About How Judicial Bias Can Influence Rulings
• DuPont Dodges ERISA Suit Thanks To 'Confusion'
• Health Care Clashes Dominate 1st Trump-Biden Debate
• Allergan Investors Lose Class Cert. Bid Over 'Serial Litigant'
• Catalyst Loses Fight Against FDA Approval Of Rival's Drug
• Patents Not 'Barrier' To COVID-19 Vaccine Access, Iancu Says
• Sterigenics Atlanta Property Value Suit May Be Premature
• Surgery Robot Maker Accused Of Banning Third-Party Repairs
• 3rd Circ. Vexed By Vagueness In Abbott Artery Device Suit
• Firm-Pharmacy Referral Deal Raises Red Flags In Mass.
• NJ Podiatrist Loses Fight Over Medical Pot Prescriptions
• Will Barrett Deliver Pivotal Vote To Strike Down The ACA?
• J&J, Mallinckrodt Push For Stay Of NY Opioid Fraud Cases
• PureShield Says Allied Bio Coronavirus Disinfectant Infringes
• Calif. Gov. Vetoes Genetic Testing Privacy Bill
• Cooley And Shearman Steer Biotech Orphazyme's $84M IPO
• Full Fed. Circ. Won't Undo Sandoz Loss In Patent Fight
• Coronavirus Regulations: A State-By-State Week In Review
• Merck, Glenmark Blast 'Extremely Small' Zetia Buyers' Class
• Law Firm Social Responsibility Strategies In The New Normal
• Dental Supply Investors Get Class Cert. In Price-Fixing Suit
• Calif. To Manufacture Its Own Generic Drugs Under New Law
• Ga. Justices Revive Claims In Sperm Bank Sham-Donor Suit
• Pomerantz To Lead Endo Investor Suit Over Opioid Crisis
• Hoffmann-La Roche Can't Shake $1.4B Tamiflu FCA Suit
• Stimwave Founder's Credibility Under Fire At Legal Fee Trial
• Global Opioid Deal In Doubt After 6th Circ. Class Ruling
• Energy Giants Agree To Make EEOC Diversity Data Public
• Judge OKs Worker's Suit Under Pa. Medical Marijuana Law
• Walmart Beats Ex-Pharmacist's Bid To Revive Opioid FCA Suit
• What To Expect On Key Civil Procedure Issues From Barrett
• Blank-Check Sponsors Get Creative In Crowded Market
• Teva Fails To Get $110M Drug Contract Suit Tossed
• Fed. Circ. Revives Jury Ax Of Biogen MS Drug Patent
• What Should A GC Do When The Boss Is Mentally Unfit?
• IUD Users Want Teva Defect Suits Sent To Calif. MDL
• NY Man Charged With COVID-19 Price-Gouging To Donate PPE
• How Law Articles And A Viral Clip Got Barrett The Nomination
• What Happens Now That Amy Coney Barrett Is The Nominee
• Judge Amy Coney Barrett: 7th Circ. Decisions To Know
• Among Democrats, A Growing Appetite To Alter High Court
• What A 6-Vote Majority Would Mean For The Supreme Court
• Judge Barrett Worth Nearly $2M, Disclosures Show
• A History Of Supreme Court Confirmations In 3 Charts
• Trump Chooses Amy Coney Barrett For Ginsburg's Seat
• Dem Reps. Eye High Court Term Limits, Temporary Expansion
• Direct Listings Highlight Busy IPO Week Involving 12 Firms
• Dems Call To Investigate DOD's CARES Act Spending
• Principia Investor Sues For Records On $3.7B Sanofi Deal
• ViSalus Pushes For Trial Redo In $925M Robocall Dispute
• NJ's The Place For Eye Damage MDL, Patients Say
• Mass. AG Says Firm Took Kickbacks To Refer Opioid Patients
• Minority Atty Group Honors Genentech For Diversity Efforts
• Care.com Escapes Investors' Background Check Suit
• Merck Urges Justices To Save Historic $2.5B Patent Verdict
• Gov't Contractors Agree To Pay $900K After Race Bias Probes
• Investor Sues $2.6B Allergy Drugmaker Over Nestle Deal
• Medical Science Co. Wants Hiscox To Foot False Ad Defense
• SEC Says Biotech Boss Conned Investors Over COVID-19 Test
• A Likely Tipping Point For Nonlawyer Ownership Of Law Firms
• The Challenges Facing Trump's Drug Pricing Order
• Ohio Medical Pot Co. Demands Action On Expansion Request
• Shareholders Must Cover Successors' Costs In Aspirin Suit
• Pot Retailer Ignored Routine Sexual Harassment, EEOC Says
• Beware DOJ's Statutory Tool For Fighting COVID-19 Fraud
• UK Litigation Roundup: Here's What You Missed In London
• FDA OKs Import Of Some Prescription Drugs From Canada
• 3 Highlights As Trump Makes Flimsy Vow On ACA Protections
• Pot Co. Says NJ Rival Can't Jump Line For Hoboken Spot
• Appeal 'Overlap' Preserves Akebia Kidney Drug Coverage Suit
• Nevada Regulator Seeks 10-Year Ban For Pot Co.
• J&J, Bausch Look To Finally Flush Talc False Ad Suit
• Patients Say Suit Over Faulty Embryo Tank Not Too Verbose
• MLB Union Slams Opposing Counsel's Ethics In Sanctions Bid
• D.C. Circ. Ponders $600M Rebate Switch Against Mallinckrodt
• Bain-Led Group Inks $2.5B Take-Private Deal With Fiber Co.
• DOJ Support Of SEP Injunctions Should Stabilize Licensing
• Bard Strikes $60M Multistate Deal Over Pelvic Mesh Marketing
• A Road Map For Drafting Persuasive Discovery Motions
• Opioid MDL Negotiating Class Struck Down By 6th Circ.
• Veteran Mental Health Bill Sent To Trump, Other Bills Proceed
• DC Circ. Mulls Vape Makers' Challenge To FDA E-Cig Rule
• Trump's COVID-19 Response Based On Science, Officials Say
• Gilead To Pay $97M To Resolve Copay Kickback Claims
• Boehringer Escapes Suit Over Underfilled Inhalers
• Shire Fights Latest Class Rep In ADHD Drug Antitrust Suit
• Drug Distributors Seek Out Of W.Va. Opioid Bellwether
• Former Pharma Exec Settles SEC Insider Trading Claim
• 3 Firms Win Lead Counsel Roles In Insulin Price-Fixing MDL
• AmerisourceBergen Says Chancery Records Ruling Too Broad
• How Congress Can Depoliticize The Supreme Court
• 5 Ways Retailers Can Mitigate Product Liability Litigation Risk
• Supplement Maker Can't Erase Anti-Aging Fraud Suit In NJ
• Weil Conflict Tainted Insys Exec's Conviction, 1st Circ. Told
• The Case For A Nonpolitical Federal Judiciary
• Pharmacies Lose Bid To Revisit Ruling On Their Opioid Duties
• Chubb Must Defend Rite Aid In Opioid Suits, Del. Court Says
• Takeda Subsidiary Seeks $130M For Drug Firm's Spinoff Fraud
• EU Told That COVID-19 Vaccine Makers Shouldn't Be Liable
• California Consumers Lose Bid For Subclass In Lipitor Case
• ITC Will Review Allergan's Win In Botox Trade Secrets Case
• Coronavirus Regulations: A State-By-State Week In Review
• Feds Slam Regeneron's Attempt To Duck Kickback Suit
• Vt. Legislators Approve Recreational Cannabis Sales, Tax
• Trustee Bristles At New $45M Purdue Bid For Ch. 11 Bonuses
• Catalyst Says FDA Is Breaking Law By Approving Rival's Drug
• Trump's Drug Pricing Order Is More Bark Than Bite
• More Ill. Sterilization Cos. Face Residents' Air Pollution Suits
• Key Regulatory Concerns For Cos. Making COVID-19 Products
• The Keys To A Better Privilege Logging Paradigm
• Justice Ginsburg: Who She Was, How She Shaped The Law
• Law360's The Term: The Life And Legacy Of Justice Ginsburg
• Philip Morris Investors Can't Revive Suit Over E-Cig Sales
• Budding Textualist Star Barbara Lagoa Eyed For High Court
• Sens. Call Purdue CEO Bonus An 'Affront' To Opioid Victims
• McConnell Defends Election-Year Plan To Replace Ginsburg
• House Passes Bill Allowing FDA To Seize Counterfeits
• Labor Unions Appeal Akorn's Ch. 11 Plan Confirmation In Del.
• Mass. Pot Co. Says Regulator Sat On Application For Months
• 3 Key Developments As US Coronavirus Deaths Near 200,000
• Home Depot Ducks Roundup Cancer Warning Suit, For Now
• Zetia Buyers Fight Quick Appeal Of Antitrust Class Cert.
• Nerve Repair Co. Didn't Even Read Claims, Investor Says
• Buyers Fight CVS, Walgreens' Bid To Exit Blood Pressure MDL
• Health Experts Detail COVID-19 Vaccine Trial For Navajo
• White House Due Process Memo Could Reform Enforcement
• Cravath, Latham Craft $8B Deal For Cancer Detection Biz
• Birthdays, Weddings And In Between: RBG And Her Clerks
• Our 'North Star': What RBG Means To Women In Law
• Will The Senate Replace Ginsburg Before Election Day?
• 5 To Watch As GOP Races To Fill Ginsburg's Seat
• RBG's Biggest Opinions, From Civil Rights To Civil Procedure
• Roundup Atty Gets 2 Years For $200M Extortion Plot
• House Forwards Bill On Counterfeit Medical Devices
• High Court Told $268M Hearing Aid Patent Award Flouts Law
• Pot Co. Can't Get Rehearing In License Ownership Dispute
• 12 Firms To Guide IPOs Exceeding $2B As September Sizzles
• In Her Own Words: 4 Of Ginsburg's Strongest Bench Dissents
• Cannabis Regs: NJ Clears New Dispensary Amid License Suit
• With The Passing Of Ginsburg, The Left Loses An Icon
• Justice Ginsburg, 87, Dies Of Cancer Complications
• Gilead Accused Of Paying To Stave Off HIV Drug Competition
• Alzheimer's Biotech Leads Trio Of IPOs To Raise $428M Total
• Wholesaler Fights To Stay Suboxone Product-Hop Class Rep
• 3 Things Attys Still Want To See On IRS Cannabis Website
• Lawmakers Say Akin Gump Report Doesn't Clarify Kodak Loan
• Merck Says Vaccine Buyers Must Arbitrate Antitrust Suit
• Law Firm Hiring Considerations In A COVID-19 Economy
• Kaplan Fox Nabs Lead In Investors' Rapid Virus Tests Suit
• How Pharma Cos. Can Evaluate Alliance Agreements' Validity
• Derivative Suit Says Biotech Co. Lied About COVID-19 Vaccine
• 3rd Circ. Backs Allergan's Win In ERISA Suit Over Drug Prices
• Hagens Berman Inks Deal To End Pa. Legal Malpractice Suit
• Federal Court Wipes Hands Of Maryland Pot Licensing Fight
• Feds Resist Merging Kickback Suits Against Teva, Regeneron
• Ixchel Loses 9th Circ. Appeal In Antitrust Row With Biogen
• NY Files Charges Against J&J Over Opioid Marketing
• Ashland Plant Workers Win Approval For $3.9M Wage Deal
• Purdue Wants Opioid Suit Ch. 11 Shield Extended To March
• Bristol Myers, Dr. Reddy's Settle Revlimid Patent Suits
• Feds Want In On Private Price-Fix Suits Versus Teva
• K&L Gates Snaps Up Calif. IP Pro From Knobbe Martens
• Energy, Biotech Companies Float IPOs Totaling $575M
• 5 More Companies Raise $2.4B As IPO Market Keeps Rolling
• Fed. Circ. Constraints On PTAB Expertise Are Problematic
• Pot Co.'s Ex-GC Says He Was Fired Over Age, Whistleblowing
• South Dakota Neurosurgeon Can't Dodge FCA Suit
• GNC Gets Nod For $770M Ch. 11 Sale To Harbin Pharma
• House Dems Delay Vote To Deschedule Marijuana
• Anthem Slips Pharmacy's Suit Over Alleged Network Shutout
• Lawyers Must Act To Preserve Democracy This Election
• Natera Fights Illumina's Bid To Invalidate DNA Testing Patent
• SDNY Judge Says She's 'DONE' With Serenity, Ferring IP Case
• Akin Gump's Probe Of Kodak Loan Finds No Law Violations
• USPTO Defers Fees On COVID-19 Provisional Applications
• Akerman Guides Fla. Pot Giant Trulieve's $66M Entry Into Pa.
• 7 Firms Steer 3 More IPOs Totaling $909M In Red-Hot Market
• W.Va. Ax Of Biogen MS Drug Patent Binds Del. Litigation
• HHS Unveils Vaccine Rollout Details As Dems Seek Oversight
• Real Estate Rumors: ESJ, Opentrons, Cars.com
• Senate IP Chair Floats Patent Transparency Program To Iancu
• Kirkland Alum Among 2 Prosecutors Tapped For Tenn. Bench
• Patients' Groups Drop Suit Over Utah's Medical Pot Law
• Dollar General Hit With False Ad Suit Over Infant Pain Reliever
• How To Effectively Defend Witnesses In Remote Depositions
• Mo. Agency Evasive In Medical Pot Investigation, Report Says
• Stryker Awarded $2.5M Pre-Filing Interest In Insurance Fight
• Rejected Pa. Medical Pot Licensee Has Right To See Score
• 11th Circ. Won't Toss $2M Verdict Against RJ Reynolds
• Pa. Medical Pot Applications Should Be Public, Justices Hear
• Bayer's Roundup Settlements Back On After 'Slight Hiccup'
• Ex-Acclarent Execs Can't Slip Misbranding Convictions
• Bernstein Litowitz, Kessler Topaz Lead Mylan Stock-Drop Suit
• Kirkland Guides Health-Focused SPAC's $500M IPO Plans
• Dana-Farber Tells Fed. Circ. Not To Revisit Inventorship Ruling
• Sidley, Latham Steer Dialysis Co. Outset's Upsized $242M IPO
• DC Circ. Urged To Rethink HHS Cuts To Hospital Payments
• J&J Workers Fight To Keep Asbestos ERISA Suit Alive
• House Dems Urge Justices To Hear Pot Legalization Fight
• Whether And How To Compel Remote Arbitration
• The Hurdles In Defending COVID-19 Contract Nonperformance
• 9th Circ. Doubts Drugmakers' Bid To Revive Free Speech Suit
• Dems Say Trump Appointees Politicized CDC Virus Reports
• Cannabis Attys Press Justices To Hear Pot Legalization Case
• Scripps Research Pays $10M To Settle Federal Grant FCA Suit
• Discovery OK'd In Pfizer Dispute With IRS For Tax Interest
• GNC Nixes Ch. 11 Auction To Go With $770M Harbin Deal
• Trump's Latest Drug Pricing Executive Order Draws Doubts
• PE-Backed GoodRx Leads 4 IPO Launches Totaling $1.4B
• Coronavirus Q&A: Venable's FDA Co-Chair
• Trulieve Says Canadian Listing Bars Securities Suits
• 4 Inventorship Lessons From Fed. Circ.'s Dana-Farber Ruling
• Pot Co. Beats Wrongful Firing Claim In Tax Scheme Suit
• The Unique Challenges Of Protecting A Law Firm Brand
• ITC Says US Methionine Biz Likely Hurting From Imports
• Merck Strikes Total $1.7B Collabs With Cancer Biotech Co.
• 2nd Circ. Reinstates NY Tax On Opioid Distributors
• Pot Biz Can Use Alternate Tax Accounting Method, IRS Says
• Actavis $19M Deal In ADHD Drug Antitrust Suit Gets Initial OK
• Davis Polk, Wachtell Build Gilead's $21B Immunomedics Buy
• Judge Slams Hagens Berman's Pause Bid As Stalling Tactic
• Neb. Medical Pot Backers Say Court Ruling Won't Stop Them
• 15 Firms To Steer IPOs Totaling $6.7B Amid Market Blitz
• Former PetMed Execs Ink $2.5M Deal To End SEC Suit
• 5th Circ. Asked To Revive Claims Drugs Caused Disease
• ADHD Med Buyers Can't Yet Appeal Class Cert. Denial
• Fla. High Court Again Told Medical Pot Law Unconstitutional
• Denali's Directors 'Grossly' Overpaid, Chancery Suit Says
• Insys Boss Tells 1st Circ. Feds Made Him Opioid 'Scapegoat'
• HHS Grilled Over $250M Coronavirus Publicity Campaign
• The Dollars And Sense Of Antitrust Class Certification: Part 2
• UK Litigation Roundup: Here's What You Missed In London
• Judge Rejects Vivus' Ch. 11 Plan, Wants Equity Panel Formed
• Cannabinoid Maker Hits Amyris With $881M Trade Secrets Suit
• Feds Can Test Ex-Theranos CEO's 'Mental Disease' Defense
• State AGs Say Drugmakers Want To Delay Price-Fixing Trials
• Dems Say CMS Chief Spent $6M On 'Personal Brand' Advisers
• Teva Severance Pay Claim Is Sent To State Court
• Neb. Supreme Court Blocks Medical Pot Initiative From Ballot
• Illumina Must Let Inventors Be Deposed In DNA Patent Suit
• Ex-BigLaw Atty Takes 3-Year Suspension For Insider Trading
• Green Thumb Says Botched Appraisal Forced It To Overpay
• FDA Warns Websites Over Illegal Opioid Sales
• Takeda Plasma Co. Hit With Ill. Finger Scan Privacy Claims
• True Health's Ch. 11 Confirmation Affirmed Over Feds' Protest
• Judge Trims Invisalign Maker Shareholder Suit
• 5 Noncompete Developments To Watch For As 2020 Ends
• Takeaways From DOJ Civil Division's Inability-To-Pay Memo
• 3 Developments As Trump Admits Downplaying Virus Threat
• Drugmakers Want Zetia 'Shortcut' Cert. Short-Circuited
• France Fines Pharma Cos. €444M For Abuse Of Dominance
• 3D Software Provider Leads 4 IPO Launches Totaling $1.5B
• House Committee Advances Medical Marijuana Research Bill
• Columbia Care Can't Dodge Fla. Pot Trade Secret Fight
• Doctor Says FDA Made Wrong Call On Opioids In NY AG Suit
• Amneal Gets Del. Judge To Invalidate Estrogen Patch IP
• W.Va. Opioid Trial Prep Under Time Crunch Due To Pandemic
• Ex-Analysts Pitch Insider Trading Challenge To High Court
• Inventor Can't Use Iancu's St. Jude Conflict To Ditch IPR
• Key FDA Drug Inspection Challenges Amid COVID-19
• WilmerHale Builds Life Sciences Presence With Boston Hire
• What To Know When Making Dispositive Motions In Arbitration
• Ex-GC Nets Early Win Against CBD Cos. Over Stocks, Benefits
• Glaxo Loses Appeal For Asthma Inhaler Color Trademark In EU
• Big Pharma CEOs Vow No Shortcuts On COVID-19 Vaccine
• Fed. Circ. OKs Cattle Breeding Patent, Kolcraft's $4.4M Win
• Justices Urged To Weigh Ex-NFL Player's Pot Legalization Bid
• Indivior Wants Class Rep DQ'd In Suboxone Product-Hop Suit
• Senate GOP Unveils 'Targeted' COVID-19 Relief Package
• Democratic AGs Return Fire In High Court Abortion Pill Row
• CBP Must Secure Lapsing Medical Contract, Watchdog Warns
• Insurer Loses 3rd Circ. Coverage Row Over Drug Trial Suit
• Michigan City Beats Medical Marijuana Permit Fight
• Fresenius Accuses Rival Of Infringing Naropin Patent
• FTC Says 3rd Circ. Ruling Can't Help AbbVie In AndroGel Case
• Ohio Counties Blast Pharmacies' Review Bid In Opioid MDL
• Ex-Insys Execs Cite Virus, Family In Bid To Delay Sentences
• Coronavirus Regulations: A State-By-State Week In Review
• 4 Ways Amicus Briefs Can Support An Overall Legal Strategy
• High Court Should Review Horizon Arthritis Drug Patent Case
• 'You Lose,' Fed. Circ. Judge Says In Cattle Breeding IP Fight
• 7th Circ. Told Insurer Has No Duty To Cover $3.3M TCPA Deal
• Express Scripts Defeats Patient Poaching Appeal At 8th Circ.
• Md. Pot Agency Says Probe Finds No Bias In License Process
• HHS Unit Probes Funding For Moderna's Patented Vaccines
• Calif. Judge Rules Cyan Loophole 'Not Illegal' Under State Law
• Fed. Circ. Judge Wary Of St. Jude Heart Valve Patent Defense
• Brand Battles: Johnson & Johnson Rips On 'Handaid' TM
• Ferring Fights To Revive Drug IP Inventorship Dispute
• Taxation With Representation: Debevoise, Wilson, Mayer
• Drug-Device Combos Divide Orange Book Feedback
• Stryker, XL Clash Over Interest After Insurance Verdict
• Buchanan Ingersoll Taps Litigator To Chair 4 Fla. Offices
• Akorn Ch. 11 Plan Confirmed Over MDL Plaintiffs' Objection
• The Enforcement Vacuum Surrounding 340B Drug Pricing
• Teva's $23B Opioid Litigation Deal Faces New Wave Of Attacks
• Cocrystal Pharma's Reforms To End $27M Stock Plot Suits
• 2 FCA Defenses Can Address Vague Pandemic-Related Rules
• Deciding Whether Co-Mediation Is Right For Your Case
• 3 Trends To Watch As Fall IPO Pipeline Gets Ready To Burst
• I-Mab Bags AbbVie Partnership, Nets $418M From Investors
• Supplement Co.'s $925M Loss A Wake-Up Call On Robocalls
• Boehringer Blocked From Making False GSK Inhaler Claims
• Investor Sues To Halt J&J's $6.5B Momenta Buy
• Nats Catcher Drops MLB Drug Suspension Challenge
• Humana's Glumetza Suit Too Little, Too Late, Court Told
• 4th Circ. Halts Trump Admin.'s Abortion Referral Rule
• DOJ Environment Chief To Take Helm At Civil Division
• Fed. Circ. Won't Revive Amarin's Vascepa Patents
• Coronavirus Litigation: The Week In Review
• 5 Steps To Help Universities Manage Foreign Influence Risk
• Activists Expand Effort To Expose Moderna's Vaccine Patents
• Patent License Considerations After Fed. Circ. Enbrel Ruling
• Wearable Medical Device Maker Raises $100M In Financing
• FAQs For 3rd Parties In Gov't Merger Suits Amid Pandemic
• Loeb & Loeb-Guided SPAC Ditches Warrants In $145M IPO
• Black Law Firm Leaders On Improving Diversity In BigLaw
• Ariz. Law Firm Ownership Rule Change Is A Win For Clients
• Emory Asks 11th Circ. To Back Win In Doctor's Race Bias Suit
• AbbVie Can't Escape Investors' Humira Kickbacks Suit
• FDA Remarks On CBD Should Restart Suit, Consumers Say
• Perrigo Fights AbbVie's Bid To Send Pa. Antitrust Suit To NJ
• J&J's South Carolina Appeal Ends After Plaintiffs Drop Cases
• 5th Circ. Rules Ex-Stryker Worker Owes Co. $2.3M In Atty Fees
• $184M Settlements OK'd In Loestrin Buyers' Antitrust Row
• 3 Firms Guide $568M Biopharma Go-Public Deal
• 15 Years Of Ohio Product Law Have Been Good For Cos.
• House To Probe Pandemic Deals Brokered By Trade Adviser
• Wash. AG Sues Juul Over Youth Marketing
• White & Case Guides Life Sciences SPAC To $385M IPO
• How To Write A Better Comment Letter On Agency Proposals
• Israeli Co.'s $20M Float Sinks Amid Life Science IPO Wave
• Iancu Says Congress May Be Up For Patent Eligibility Reform
• AbbVie Faces House Subpoena Over Humira Pricing
• Allergan, Teva Accused Of Hiding 'Critical' Opioid Info
• SEC Pays $2.5M Whistleblower Award To Wall Street Analysts
• Monsanto Asks Calif. High Court To Ax Cancer Liability Loss
• Kite Pharma Wants Fed. Circ. To Nix Juno's $1.2B Patent Win
• FDA Guidance Addresses Wave Of Impurities In Popular Drugs
• CMS Wants Medicare To Cover 'Breakthrough' Devices Faster
• Akorn's Ch. 11 Sale Gets Court Approval In Del.
• ABB Optical Settles Out Of Contact Lens Price-Fix MDL
• Timely Fraud Reporting Rule Under Fire In Whistleblower Suit
• Chinese Medical Equipment Spared From Duties Until 2021
• Teva Hit With Suit In NY Over Broken Birth Control Implant
• Genetic Testing Privacy Bill Clears Calif. Legislature
• Cigna Gets Suits Over Drug Prices Pared Down
• PE Credit Considerations After IntegraMed Ch. 7 Ruling
• Coronavirus Regulations: A State-By-State Week In Review
• J&J Loses Pa. High Court Appeal Bid In $70M Risperdal Case
• The Problem With Collectability In Legal Malpractice Cases
• Dr. Reddy's Inks Deal To Exit Namenda Pay-For-Delay Suit
• Pricey Biogen 401(k) Plan Was 'Glaring Breach,' Suit Says
• Whistleblower Swap Doesn't Kill FCA Standing, 3rd Circ. Says